Clinical and immune profiling for cancer of unknown primary site-Reference-Cited by-同舟云学术

Clinical and immune profiling for cancer of unknown primary site

Published:2019-09-13 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Haratani Koji,Hayashi Hidetoshi,Takahama Takayuki,Nakamura Yasushi,Tomida Shuta,Yoshida Takeshi,Chiba Yasutaka,Sawada Takahiro,Sakai Kazuko,Fujita Yoshihiko,Togashi Yosuke,Tanizaki Junko,Kawakami Hisato,Ito Akihiko,Nishio Kazuto,Nakagawa Kazuhiko

Funder

Bristol-Myers Squibb Co. Ltd.

THE OSAKA RESEARCH FOUNDATION FOR INTRACTABLE DISEASE

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0720-z.pdf

Reference34 articles.

1. NCCN Clinical Practice Guidelines in Oncology Occult Primary. https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf .

2. Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G, et al. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v133–8.

3. Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31(2):217–23.

4. Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol. 2015;1(1):40–9.

5. Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, et al. Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol. 2019;37(7):570–9.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors;European Journal of Cancer;2024-10

2. Exploring the molecular landscape of cancer of unknown primary: A comparative analysis with other metastatic cancers;Molecular Oncology;2024-05-15

3. Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology;The Oncologist;2024-03-23

4. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer;British Journal of Cancer;2024-03-22

5. Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies;Biosensors;2024-02-16